Doubling Down on Biobot

Biobot Analytics didn’t just identify a white space—they pioneered the field of wastewater intelligence, transforming overlooked infrastructure into a predictive signal for public health. Today, Biobot is the clear leader, empowering institutions across healthcare, government, and beyond with real-time insights into disease, drug use, and community health.

We’re proud to have backed Mariana Matus and Newsha Ghaeli from Biobot’s earliest days. Today, we’re excited to double down by participating in their latest round—helping them scale a vision that is as bold as it is urgent.

Why Biobot, Why Now

Biobot’s work is built on a radical idea: that wastewater can act as a real-time health observatory—a kind of early-warning system capable of detecting infectious diseases, tracking drug use, and identifying emerging public health threats, often before they appear in clinical settings.

Their data isn’t just reactive. It’s predictive.

• Their technology has already shaped national public health strategy, from monitoring COVID-19 to identifying fentanyl and opioid trends at the state level.
• Their AI-powered dashboards now offer real-time risk tiers and infection tracking for respiratory pathogens like RSV, influenza, and more.
• Their newly launched Data-as-a-Service (DaaS) platform is gaining traction with global pharmaceutical and healthcare leaders eager to integrate population-wide insights into research, clinical trials, and strategic planning.

This is more than infrastructure—it’s a new intelligence layer for healthcare and national security.

A Founding Team for the Frontier

Biobot’s founders—Dr. Mariana Matus, a computational biologist, and Newsha Ghaeli, an urban systems designer—embody the kind of interdisciplinary vision that defines category creators.

Born at MIT, Biobot began with a PhD thesis and a bold hypothesis: that sewers could become observatories for population health. Under Mariana and Newsha’s leadership, that vision has evolved from academic insight to commercial reality, delivering measurable impact in over 700 cities across the U.S.—and counting.

What sets this team apart is their scientific rigor, clarity of execution, and commitment to public impact. Their majority-women leadership team brings deep expertise across biology, AI, policy, and systems operations—positioning Biobot to navigate complexity with purpose and precision.

Their work has earned recognition not just for innovation, but for impact—with honors including TIME100 Most Influential Companies, TIME Best Inventions, CNBC’s Disruptor 50, Fast Company’s Most Innovative Companies, Newsweek’s Greatest Disruptors, and Smart Cities Dive’s Technology of the Year, along with sustained recognition on the GovTech 100 list.

Strategic Execution Meets Expanding Market Opportunity

Biobot’s trajectory has followed a clear and powerful arc:

• Early success in state-level opioid monitoring
• National deployment with the CDC during the COVID-19 pandemic
• Deep technical buildout, including assays for 30+ pathogens and robust AI models
• Productization through a rapidly growing DaaS customer base among global pharma and biotech leaders

Now, the company is expanding into chronic disease monitoring, international markets, and biosecurity—scaling into a $50B+ global opportunity with transformative societal implications.

We’re All In

Biobot is redefining what’s possible in public health—rooted in rigorous science, powered by real-time data, and scaled through disciplined execution. This isn’t just a new product category—it’s a new public health paradigm.

We’re proud to stand alongside Mariana, Newsha, and the entire Biobot team as they build the health intelligence infrastructure of the future.

This isn’t just another round—it’s a renewed commitment to better data, better systems, and a healthier, more resilient world.

‍